Decreased density of i2imidazoline receptors in the postmortem brains of heroin addicts

NeuroReport

Volumn 7, Issue 2, 1996, Pages 509-512

  Sastre, Magdalena ^a   Ventayol, Pere ^a   García Sevilla, Jesús A ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

Heroin addiction; Human and rat brain; I2 imidazoline receptors; Imidazoline receptor proteins; Western immunoblot; 3H idazoxan binding

Indexed keywords

DIAMORPHINE; DRUG RECEPTOR; IDAZOXAN; IMIDAZOLINE RECEPTORS; TUBULIN; IMIDAZOLINE RECEPTOR;

ADOLESCENT; ADULT; ANIMAL; ARTICLE; BRAIN LEVEL; DOWN REGULATION; DRUG EFFECT; FEMALE; HEROIN DEPENDENCE; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; KINETICS; MALE; METABOLISM; PHYSIOLOGY; RADIOASSAY; RAT; SPRAGUE DAWLEY RAT; CLINICAL ARTICLE; CONTROLLED STUDY; FRONTAL CORTEX; HUMAN TISSUE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DOWN REGULATION;

ADOLESCENT; ADULT; ANIMALS; BRAIN CHEMISTRY; DOWN-REGULATION; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; IDAZOXAN; IMMUNOBLOTTING; KINETICS; MALE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; TUBULIN;

EID: 0029670053     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199601310-00032     Document Type: Article

References (25)

1. Nestler EJ. J Neurosci 12, 2439-2450 (1992).
2. García-Sevilla JA, Ugedo L, Ulibarri I et al. Eur J Pharmacol 114, 365-374 (1985).
3. García-Sevilla JA, Ulibarri I, Ugedo L et al. Psychopharmacology 92, 320-323 (1987).
4. Ulibarri I, García-Sevilla JA, and Ugedo L Naunyn Schmiedeberg's Arch Pharmacol 336, 530-537 (1987).
5. Aghajanian GK. Nature 276,186-188 (1978).
6. Gold MS, Redmond DE Jr and Kleber HD. Lancet ii, 599-602 (1978).
7. Michel MC and Insel PA. Trends Pharmacol Sci 10, 342-344 (1989).
8. Li G, Regunathan S, Barrow CJ et al. Science 263, 966-969 (1994).
9. Michel MC and Ernsberger P. Trends Pharmacol Sci 13, 369-370 (1992).
10. García-Sevilla JA, Miralles A, Sastre M et al. Ann NY Acad Sci 763, 178-193 (1995).
11. Kolesnikov Y, Jain S and Pasternak GW. Eur JPharmacol (1995). In press.
12. Escribá PV, Sastre M and García-Sevilla JA. Arch Gen Psychiatry 51, 494-501 (1994).
13. Miralles A, Olmos G, Sastre M et al. J Pharmacol Exp Ther 264, 1187-1197 (1993).
14. Wang H, Regunathan S, Meeley MP et al. Mol Pharmacol 42, 792-801 (1992).
15. Escribá PV, Sastre M, Wang H et al. Neurosci Lett 178, 81-84 (1994).
16. Escribá PV, Ozaita A, Miralles A et al. Mol Brain Res 32, 187-196 (1995).
17. García-Sevilla JA, Sastre M and EscribáPV. Neurosci Lett 184, 133-136 (1995).
18. Regunathan S, Feinstein DL and Reis DJ. J Neurosci Res 34, 681-688 (1993).
19. Olmos G, Alemany R, Escribá PV et al. Br J Pharmacol 111, 997-1002 (1994).
20. Eriksson PS, Hansson E, Rönnbäck L. Neurochem Res 15, 1123-1126 (1990).
21. Rady JJ, Aksu F and Fujimoto JM. J Pharmacol Exp Ther 268, 1222-1231 (1994).
22. Ruggiero DA, Regunathan S, Wang H et al. Ann NY Acad Sci 763, 208-221 (1995).
23. Stiene-Martin A and Hauser KF. Neurosci Lett 157, 1-3 (1993).
24. Zagon IS and McLaghlin PJ. Brain Res 412, 68-72 (1987).
25. Hauser KF and Stiene-Martin A. Dev Brain Res 62, 245-255 (1991).